SGLT2 inhibitors also reduced the composite of cardiovascular death or hospitalization for heart failure by 29–31% in patients with CKD with or without T2DM, CVD or a history of HF (25, 26). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.